Blog

Kamal S. Saini: Enrollment is Ongoing for Phase 3 study CAMBRIA-1

Photo taken from Kamal S. Saini/LinkedIn

May 26, 2024, 08:16

Kamal S. Saini: Enrollment is Ongoing for Phase 3 study CAMBRIA-1

Kamal S. Saini, Executive Medical Director and Head of European Medical Oncology Team at Fortrea Inc., made the following post on LinkedIn

“Approximately 4300 pts will be randomized into the early breast cancer Phase 3 study CAMBRIA-1; enrollment is ongoing!

A phase 3 randomized open-label study of extended adjuvant therapy with camizestrant vs standard endocrine therapy in patients with ER+/HER2– early breast cancer and an intermediate or high risk of recurrence (CAMBRIA 1)
Erika Hamilton; Sibylle Loibl; Naoki Niikura; Priya Rastogi; Kamal S. Saini; Ioanna Gioni; Teresa Klinowska; Ingrid A. Mayer; Mary Stuart; Emilia Syta; Andrew Walding; Thomas Bachelot.”

Kamal S. Saini

Read further.
Source: Kamal S. Saini/LinkedIn
.

4300 pts Andrew Walding CAMBRIA-1 camizestrant cancer early breast cancer Emilia Syta enrollment ongoing ER+/HER2– Erika Hamilton Executive Medical Director extended adjuvant therapy Fortrea Inc. Head of European Medical Oncology Team high risk of recurrence Ingrid A. Mayer intermediate risk Ioanna Gioni Kamal S. Saini Mary Stuart Naoki Niikura OncoDaily Oncology Phase 3 study Priya Rastogi randomized open-label study Sibylle Loibl standard endocrine therapy Teresa Klinowska Thomas Bachelot

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage